Übersetzung für "Chronischer schmerz" in Englisch

Chronic pain just doesn't go away overnight.

He's a pest, a chronic pain.

How does chronic pain impact on a person's powers of concentration?

What is ‘chronic’ pain?

Chronic, unrelieved pain is a major unsolved healthcare problem in Europe.

Chronic pain is a very common disease.

However there are very basic differences between acute and chronic pain.

Chronic pain is an example.

Chronic pain destroys lives and we have few tools at our disposal.

Chronic pain is a major reason that patients search for remedies through alternative and complementary treatments.

The extent to which chronic pain is caused by biological, psychological or social factors depends on the individual.

In some cases, chronic pain can be caused by genetic factors which interfere with neuronal differentiation, leading to a permanent reduction in the threshold for pain.

But evolution has failed to keep pace with biomedical and technological advances, allowing chronic pain (pain that persists beyond an acute injury or condition) to become a disease in itself.

A popular alternative definition of chronic pain, involving no arbitrarily fixed duration, is "pain that extends beyond the expected period of healing".

If the pain persists beyond the period of the expected recovery (about 3-6 months), it is defined as chronic pain.

Chronic pain is one of the most costly health issues for industrialized countries and the number one reason for health-related absence from labor and early retirement.

Less chronic pain, less suffering, greater productivity – we can achieve it, but it won’t come for free.”

Chronic pain is a severely impairing condition, which leads to high costs for the health care system; so far, however, it is not sufficiently treatable.

Despite its socio-economic impact healthcare systems and policy-makers across Europe oftentimes do not recognize chronic pain as a disease in its own right.

Research shows us that insomnia is typically a symptom of a separate condition (i.e., depression or a chronic pain condition) as opposed to a condition in and of itself.

Chronic pain is included in the beta version of the ICD's 11th revision, which will be tested in practice until August 2016, with subcategories such as chronic primary pain, chronic postsurgical pain, chronic neuropathic pain, and chronic headache and orofacial pain.

These disorders include chronic inflammatory and autoimmune diseases (such as, for example, Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, multiple sclerosis, lupus, asthma, diabetes), cardiovascular disorders (such as, for example, coronary heart disease, myocardial infarction, atherosclerosis, restenosis, thromboses), fibrotic disorders of the liver and other organs, cerebrovascular disorders (such as, for example, stroke, craniocerebral trauma, spinal cord injuries) and chronic neurodegenerative disorders (such as, for example, Alzheimer's disease, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis, peripheral neuropathies and chronic pain).

The compounds according to the invention are potent inhibitors/modulators of NF-kB and/or AP-1 activity and are suitable as such in particular for the treatment of chronic inflammatory and autoimmune diseases (such as, for example, Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, multiple sclerosis, lupus, asthma, diabetes), cardiovascular disorders (such as, for example, coronary heart disease, myocardial infarction, atherosclerosis, restenosis, thromboses), fibrotic disorders of the liver and other organs, cerebrovascular disorders (such as, for example, stroke, craniocerebral trauma, spinal cord injuries) and chronic neurodegenerative disorders (such as, for example, Alzheimer's disease, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis, peripheral neuropathies and chronic pain).

Therein, the term “chronic pain”, amongst others, comprises neuropathic pain, and inflammatory and tumor-related pain.

In addition to the indications mentioned, IRAK4 inhibitors are also suitable for the treatment and/or prevention of neurological disorders mediated by the IL-1 receptor family, such as stroke apoplexy, Alzheimer's disease, stroke, skull-brain trauma and pain such as cancer pain, postoperative pain, inflammation-induced pain and chronic pain (Wolf, Livshits, et al., Brain, Behavior, and Immunity, 2008;